Phase 2 trial in 107 participants with chronic active pulmonary sarcoidosis: namilumab did not reduce rescue events vs placebo (37.5% vs 23.5%; p=0.12) and fewer achieved corticosteroid taper (53.3% vs 76.9%); no clinical benefit.
RCTn = 107
Van Den Blink et al. Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study